Currently Enrolling:
For patients with Alport Syndrome:
- An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE). Learn more about this trial.
For patients with IgA Nephropathy:
- A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS). Learn more about this trial.
Enrollment beginning soon:
For patients with Diabetic Nephropathy:
- A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease (MANUEVER). View the clincialtrials.gov listing.
For patients with Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, or Treatment-Resistant Minimal Change Disease:
- A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease (GFB-887). View the clinicaltrials.gov listing.
Additional trials will be added as they are available.
